Biomarkers in cancer最新文献_第3页

In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer. 寻找结直肠癌腹膜转移术中荧光成像的最佳靶点。

Biomarkers in cancer Pub Date : 2017-08-28 eCollection Date: 2017-01-01 DOI: 10.1177/1179299X17728254

Charlotte Es Hoogstins, Benjamin Weixler, Leonora Sf Boogerd, Diederik J Hoppener, Hendrica Ajm Prevoo, Cornelis Fm Sier, Jacobus Wa Burger, Cornelis Verhoef, Shadvhi Bhairosingh, Arantza Farina Sarasqueta, Jacobus Burggraaf, Alexander L Vahrmeijer

{"title":"In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer.","authors":"Charlotte Es Hoogstins, Benjamin Weixler, Leonora Sf Boogerd, Diederik J Hoppener, Hendrica Ajm Prevoo, Cornelis Fm Sier, Jacobus Wa Burger, Cornelis Verhoef, Shadvhi Bhairosingh, Arantza Farina Sarasqueta, Jacobus Burggraaf, Alexander L Vahrmeijer","doi":"10.1177/1179299X17728254","DOIUrl":"https://doi.org/10.1177/1179299X17728254","url":null,"abstract":"Peritoneal metastasis (PM) occurs in about 10% of patients with colorectal cancer (CRC). Fluorescence imaging can enhance contrast between cancerous and benign tissue, enabling the surgeon to clearly visualize PM during cytoreductive surgery. This study assessed the suitability of different biomarkers as potential targets for tumor-targeted imaging of PM of CRC. Tissue samples from primary tumor and PM from patients with CRC were obtained from the pathology archives and immunohistochemical stainings were performed. Overexpression of the epithelial cell adhesion molecule (EpCAM) and carcinoembryonic antigen (CEA) was seen in 100% of PM samples and the expression was strong in >70% of samples. Tyrosine-kinase Met (C-Met) and folate receptor α overexpression was seen in 20% of PM samples. For successful application of tumor-targeted intraoperative fluorescence imaging of PM, biomarkers need to be identified. We demonstrated that both EpCAM and CEA are suitable targets for fluorescence imaging of PM in patients with CRC.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":" ","pages":"1179299X17728254"},"PeriodicalIF":0.0,"publicationDate":"2017-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179299X17728254","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35327848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank. 分析 Fascin-1 与人类前列腺癌 Gleason 风险分类及核 ETS 相关基因状态的关系：威尔士癌症库临床注释肿瘤的免疫组化研究。

Biomarkers in cancer Pub Date : 2017-05-30 eCollection Date: 2017-01-01 DOI: 10.1177/1179299X17710944

Matthew T Jefferies, Christopher S Pope, Howard G Kynaston, Alan R Clarke, Richard M Martin, Josephine C Adams

{"title":"Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank.","authors":"Matthew T Jefferies, Christopher S Pope, Howard G Kynaston, Alan R Clarke, Richard M Martin, Josephine C Adams","doi":"10.1177/1179299X17710944","DOIUrl":"10.1177/1179299X17710944","url":null,"abstract":"Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer. Fascin-1 was elevated in focal areas of a minority of tumours, yet fascin-1-positivity did not differentiate tumours of low-, intermediate-, or high-risk Gleason scores and did not correlate with PSA status or biochemical relapse after surgery. Stromal fascin-1 correlated with high Gleason score. Nuclear ERG was upregulated in tumours but not in stroma. The complexities of fascin-1 status indicate that fascin-1 is unlikely to provide a suitable biomarker for prediction of aggressive prostate cancers.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":" ","pages":"1179299X17710944"},"PeriodicalIF":0.0,"publicationDate":"2017-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/04/10.1177_1179299x17710944.PMC5457026.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35083192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue. 术前血清癌胚抗原水平与胰腺癌和直肠癌组织表达的相关性

Biomarkers in cancer Pub Date : 2017-05-17 eCollection Date: 2017-01-01 DOI: 10.1177/1179299X17710016

L S F Boogerd, F A Vuijk, C E S Hoogstins, H J M Handgraaf, M J M van der Valk, P J K Kuppen, C F M Sier, C J H van de Velde, J Burggraaf, A Fariña-Sarasqueta, Alexander L Vahrmeijer

{"title":"Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.","authors":"L S F Boogerd, F A Vuijk, C E S Hoogstins, H J M Handgraaf, M J M van der Valk, P J K Kuppen, C F M Sier, C J H van de Velde, J Burggraaf, A Fariña-Sarasqueta, Alexander L Vahrmeijer","doi":"10.1177/1179299X17710016","DOIUrl":"https://doi.org/10.1177/1179299X17710016","url":null,"abstract":"Carcinoembryonic antigen (CEA)-targeted imaging and therapeutic agents are being tested in clinical trials. If CEA overexpression in malignant tissue corresponds with elevated serum CEA, serum CEA could assist in selecting patients who may benefit from CEA-targeted agents. This study aims to assess the relationship between serum CEA and CEA expression in pancreatic (n = 20) and rectal cancer tissues (n = 35) using histopathology. According to local laboratory standards, a serum CEA >3 ng/mL was considered elevated. In pancreatic cancer patients a significant correlation between serum CEA and percentage of CEA-expressing tumor cells was observed (P = .04, ρ = .47). All 6 patients with homogeneous CEA expression in the tumor had a serum CEA >3 ng/mL. Most rectal cancer tissues (32/35) showed homogeneous CEA expression, independent of serum CEA levels. This study suggests that selection of pancreatic cancer patients for CEA-targeted agents via serum CEA appears adequate. For selection of rectal cancer patients, serum CEA levels are not informative.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":" ","pages":"1179299X17710016"},"PeriodicalIF":0.0,"publicationDate":"2017-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179299X17710016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35060290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Biomarkers for Hepatocellular Carcinoma. 肝细胞癌的生物标志物

Biomarkers in cancer Pub Date : 2017-02-28 eCollection Date: 2017-01-01 DOI: 10.1177/1179299X16684640

Jiatao Lou, LingFei Zhang, Shaogang Lv, Chenzi Zhang, Shuai Jiang

引用次数: 170

Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers. 术前血清癌胚抗原作为预测三种癌症预后的标志物。

Biomarkers in cancer Pub Date : 2017-02-16 eCollection Date: 2017-01-01 DOI: 10.1177/1179299X17690142

Jingzhu Nan, Juan Li, Xiujuan Li, Guanghong Guo, Xinyu Wen, Yaping Tian

{"title":"Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers.","authors":"Jingzhu Nan, Juan Li, Xiujuan Li, Guanghong Guo, Xinyu Wen, Yaping Tian","doi":"10.1177/1179299X17690142","DOIUrl":"https://doi.org/10.1177/1179299X17690142","url":null,"abstract":"Background: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors.Objective: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment.Methods: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index. The data were analyzed by the Kaplan-Meier curves generated by the log-rank test and Cox multivariate analysis.Results: The overall survival rate for all the patients was 71.11%. The 3-year survival rate of patients with prostate, breast, gastric, and pancreatic cancers was 81.69%, 95.65%, 54.55%, and 51.61%, respectively. The 3-year survival rate showed significant statistical differences between patients with serum CEA levels <2.885 µg/L and those with serum CEA levels ⩾2.885 µg/L (P < .001). The statistical differences of the 3-year survival rate also existed in the men (P = .010) or women group (P < .001), as well as in the 3 different types of cancer, which include breast cancer (P = .025), gastric cancer (P = .001), and pancreatic cancer (P = .047).Conclusions: Serum CEA levels can provide additional prognostic information and may be useful in treatment implementation for patients with breast, gastric, or pancreatic cancer.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1179299X17690142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34964534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma. miR-486-3p、miR-139-5p和miR-21作为检测口腔舌鳞癌的生物标志物

Biomarkers in cancer Pub Date : 2017-01-01 DOI: 10.4137/BIC.S40981

Zujian Chen, Tianwei Yu, Robert J Cabay, Yi Jin, Ishrat Mahjabeen, Xianghong Luan, Lei Huang, Yang Dai, Xiaofeng Zhou

{"title":"miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma.","authors":"Zujian Chen, Tianwei Yu, Robert J Cabay, Yi Jin, Ishrat Mahjabeen, Xianghong Luan, Lei Huang, Yang Dai, Xiaofeng Zhou","doi":"10.4137/BIC.S40981","DOIUrl":"https://doi.org/10.4137/BIC.S40981","url":null,"abstract":"Oral tongue squamous cell carcinoma (TSCC) is a complex disease with extensive genetic and epigenetic defects, including microRNA deregulation. The aims of the present study were to test the feasibility of performing the microRNA profiling analysis on archived TSCC specimens and to assess the potential diagnostic utility of the identified microRNA biomarkers for the detection of TSCC. TaqMan array-based microRNA profiling analysis was performed on 10 archived TSCC samples and their matching normal tissues. A panel of 12 differentially expressed microRNAs was identified. Eight of these differentially expressed microRNAs were validated in an independent sample set. A random forest (RF) classification model was built with miR-486-3p, miR-139-5p, and miR-21, and it was able to detect TSCC with a sensitivity of 100% and a specificity of 86.7% (overall error rate = 6.7%). As such, this study demonstrated the utility of the archived clinical specimens for microRNA biomarker discovery. The feasibility of using microRNA biomarkers (miR-486-3p, miR-139-5p, and miR-21) for the detection of TSCC was confirmed.","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"9 ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9874790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition. 癌基因:通过PKR抑制病毒溶瘤的通行证。

Biomarkers in cancer Pub Date : 2016-07-28 eCollection Date: 2016-01-01 DOI: 10.4137/BIC.S33378

Janaina Fernandes

引用次数: 19

Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. 肝细胞癌的组织和血清相关生物标志物。

Biomarkers in cancer Pub Date : 2016-07-04 eCollection Date: 2016-01-01 DOI: 10.4137/BIC.S34413

Ranjit Chauhan, Nivedita Lahiri

{"title":"Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.","authors":"Ranjit Chauhan, Nivedita Lahiri","doi":"10.4137/BIC.S34413","DOIUrl":"https://doi.org/10.4137/BIC.S34413","url":null,"abstract":"Hepatocellular carcinoma (HCC), one of the leading causes of cancer deaths in the world, is offering a challenge to human beings, with the current modes of treatment being a palliative approach. Lack of proper curative or preventive treatment methods encouraged extensive research around the world with an aim to detect a vaccine or therapeutic target biomolecule that could lead to development of a drug or vaccine against HCC. Biomarkers or biological disease markers have emerged as a potential tool as drug/vaccine targets, as they can accurately diagnose, predict, and even prevent the diseases. Biomarker expression in tissue, serum, plasma, or urine can detect tumor in very early stages of its development and monitor the cancer progression and also the effect of therapeutic interventions. Biomarker discoveries are driven by advanced techniques, such as proteomics, transcriptomics, whole genome sequencing, micro- and micro-RNA arrays, and translational clinics. In this review, an overview of the potential of tissue- and serum-associated HCC biomarkers as diagnostic, prognostic, and therapeutic targets for drug development is presented. In addition, we highlight recently developed micro-RNA, long noncoding RNA biomarkers, and single-nucleotide changes, which may be used independently or as complementary biomarkers. These active investigations going on around the world aimed at conquering HCC might show a bright light in the near future. ","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"8 Suppl 1","pages":"37-55"},"PeriodicalIF":0.0,"publicationDate":"2016-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S34413","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34653805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 82

Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images. 从断层CT和MR图像中定量的脑癌灌注和渗透性生物标志物。

Biomarkers in cancer Pub Date : 2016-07-03 eCollection Date: 2016-01-01 DOI: 10.4137/BIC.S31801

Armin Eilaghi, Timothy Yeung, Christopher d'Esterre, Glenn Bauman, Slav Yartsev, Jay Easaw, Enrico Fainardi, Ting-Yim Lee, Richard Frayne

{"title":"Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images.","authors":"Armin Eilaghi, Timothy Yeung, Christopher d'Esterre, Glenn Bauman, Slav Yartsev, Jay Easaw, Enrico Fainardi, Ting-Yim Lee, Richard Frayne","doi":"10.4137/BIC.S31801","DOIUrl":"https://doi.org/10.4137/BIC.S31801","url":null,"abstract":"Dynamic contrast-enhanced perfusion and permeability imaging, using computed tomography and magnetic resonance systems, are important techniques for assessing the vascular supply and hemodynamics of healthy brain parenchyma and tumors. These techniques can measure blood flow, blood volume, and blood-brain barrier permeability surface area product and, thus, may provide information complementary to clinical and pathological assessments. These have been used as biomarkers to enhance the treatment planning process, to optimize treatment decision-making, and to enable monitoring of the treatment noninvasively. In this review, the principles of magnetic resonance and computed tomography dynamic contrast-enhanced perfusion and permeability imaging are described (with an emphasis on their commonalities), and the potential values of these techniques for differentiating high-grade gliomas from other brain lesions, distinguishing true progression from posttreatment effects, and predicting survival after radiotherapy, chemotherapy, and antiangiogenic treatments are presented. ","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"8 Suppl 2","pages":"47-59"},"PeriodicalIF":0.0,"publicationDate":"2016-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S31801","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34653804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Predicting Clinical Outcomes Using Molecular Biomarkers. 使用分子生物标志物预测临床结果。

Biomarkers in cancer Pub Date : 2016-06-06 eCollection Date: 2016-01-01 DOI: 10.4137/BIC.S33380

Harry B Burke

{"title":"Predicting Clinical Outcomes Using Molecular Biomarkers.","authors":"Harry B Burke","doi":"10.4137/BIC.S33380","DOIUrl":"https://doi.org/10.4137/BIC.S33380","url":null,"abstract":"Over the past 20 years, there has been an exponential increase in the number of biomarkers. At the last count, there were 768,259 papers indexed in PubMed.gov directly related to biomarkers. Although many of these papers claim to report clinically useful molecular biomarkers, embarrassingly few are currently in clinical use. It is suggested that a failure to properly understand, clinically assess, and utilize molecular biomarkers has prevented their widespread adoption in treatment, in comparative benefit analyses, and their integration into individualized patient outcome predictions for clinical decision-making and therapy. A straightforward, general approach to understanding how to predict clinical outcomes using risk, diagnostic, and prognostic molecular biomarkers is presented. In the future, molecular biomarkers will drive advances in risk, diagnosis, and prognosis, they will be the targets of powerful molecular therapies, and they will individualize and optimize therapy. Furthermore, clinical predictions based on molecular biomarkers will be displayed on the clinician's screen during the physician-patient interaction, they will be an integral part of physician-patient-shared decision-making, and they will improve clinical care and patient outcomes. ","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":"8 ","pages":"89-99"},"PeriodicalIF":0.0,"publicationDate":"2016-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/BIC.S33380","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34625776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 86